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ABSTRACT
Introduction: The aim of this study was to
investigate the efficacy and safety of
linagliptin ? low-dose (LD) metformin once
daily versus high-dose (HD) metformin twice
daily in treatment-naı¨ve patients with type 2
diabetes.
Methods: Patients (n = 689) were randomized
(1:1) to double-blind treatment with linagliptin
5 mg ? LD metformin (1000 mg) or HD
metformin (2000 mg) for 14 weeks. Metformin
was initiated at 500 mg/day and up-titrated
within 2 weeks; the dose then remained
unchanged. The primary endpoint was change
in glycated hemoglobin (HbA1c) from baseline
to Week 14 in patients who tolerated a daily
metformin dose of C1000 mg after 2 weeks.
Results: At Week 14, HbA1c changed from a
mean baseline of 8.0% (64 mmol/mol) by
-0.99% (-11 mmol/mol) for linagliptin ? LD
metformin, and -0.98% (-11 mmol/mol) for
HD metformin [treatment difference -0.01%
(95% confidence interval -0.13, 0.12)
(0 mmol/mol), P = 0.8924]. The proportion of
patients who achieved HbA1c \7.0%
(53 mmol/mol) without occurrence of
moderate or severe gastrointestinal (GI) events
(including abdominal pain, nausea, vomiting,
diarrhea, and decreased appetite) was the same
in both groups (51.3% for both). Although the
occurrence of moderate or severe GI events was
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similar, the linagliptin ? LD metformin group
had fewer mild GI events (18.5% versus 24.3%).
The incidence of hypoglycemia was low in both
groups.
Conclusion: Linagliptin ? LD metformin
combination showed similar efficacy and safety
to HD metformin. This combination may be an
alternative treatment option in patients who may
have difficulty tolerating metformin doses
[1000 mg/day.
Funding: Boehringer Ingelheim.
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INTRODUCTION
International guidelines for the treatment of
type 2 diabetes mellitus (T2DM) collectively
recommend metformin monotherapy, if not
contraindicated, as first-line therapy [1–3].
These guidelines advocate personalizing targets
for glycemic control, generally defined by a
glycated hemoglobin (HbA1c) level \7.0%
(53 mmol/mol) [1, 2] or B6.5% (48 mmol/mol)
[3]. However, treatment with metformin is
associated with gastrointestinal (GI) events,
including nausea, vomiting, diarrhea,
abdominal pain, and loss of appetite [1, 4].
These symptoms limit its tolerability and may
result in approximately 5% of patients
discontinuing metformin treatment [5, 6]. GI
disturbances may also reduce therapeutic
adherence, potentially contributing to
inadequate glycemic control. Therefore,
metformin is initiated at a low dose (LD) and
up-titrated to the maximum tolerated dose [1, 2].
Some guidelines advocate initial treatment
with combination therapy in patients with
baseline HbA1c levels of C9% (75 mmol/mol)
[1] or C7.5% (58 mmol/mol) [3]. This approach
may also offer advantages when drug
tolerability is a concern. For example, using
lower doses of one or both drugs in the
combination may minimize the adverse events
(AEs) associated with the respective maximum
dose monotherapies but without compromising
the overall glucose-lowering efficacy [7].
Initial treatment with LD metformin plus
another glucose-lowering drug could mitigate
the tolerability issues associated with higher
doses of metformin. LD metformin in
combination with a dipeptidyl peptidase
(DPP)-4 inhibitor is an attractive treatment
option due to their complementary
mechanisms of action which, together, target
multiple pathophysiological defects of T2DM,
with low additional risk for hypoglycemia and
weight gain. Studies have shown that
linagliptin plus metformin administered twice
daily as add-on or initial combination therapy
was effective and well tolerated for up to 2 years
[8–10]. This combination did not increase the
risk for hypoglycemia or weight gain, and GI
tolerability was similar to that of metformin
monotherapy. These results suggest this
combination might be a valuable alternative
treatment, especially for patients who do not
tolerate higher or the maximum dose of
metformin. Therefore, this study aimed to
investigate the efficacy and safety of
linagliptin 5 mg in combination with LD
metformin once daily versus high-dose (HD)
metformin twice daily in treatment-naı¨ve
patients with T2DM.
METHODS
Study Design and Patients
This phase 4, randomized, double-blind, active-
comparator controlled, parallel-group
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comparison study was performed at 88 trial
centers in 13 countries (Belgium, Canada,
China, Germany, Spain, India, Bangladesh,
Guatemala, Mexico, Peru, Taiwan, Lebanon,
and the Philippines; ClinicalTrials.gov
number, NCT01438814). The study enrolled
patients with a diagnosis of T2DM who were
aged C18 and B80 years, with a body mass
index (BMI) B45 kg/m2, and HbA1c C7.0%
(53 mmol/mol) and B10.0% (86 mmol/mol).
Patients were drug-naı¨ve, defined as an
absence of any oral or injectable
antihyperglycemic therapies for C12 weeks
before randomization.
Patients were ineligible if they had
uncontrolled hyperglycemia [glucose
level [240 mg/dL (13.3 mmol/l) during
screening or placebo run-in after an overnight
fast, confirmed by a second measurement];
acute coronary syndrome, stroke, or transient
ischemic attack within 3 months before
consent; indication of liver disease or impaired
hepatic function; impaired renal function,
defined as estimated glomerular filtration rate
(eGFR) \60 mL/min/1.73 m2 (determined
during screening or placebo run-in); bariatric
surgery within the past 2 years or other GI
surgeries that induce chronic malabsorption;
and a medical history of cancer or treatment for
cancer within the last 5 years. Further exclusion
criteria included blood dyscrasias or any
disorder causing hemodialysis or unstable red
blood cell; known history of pancreatitis or
chronic pancreatitis; contraindications to
metformin; treatment with anti-obesity drugs
within 3 months before consent or any other
treatment at the time of screening leading to
unstable body weight; and treatment with
systemic steroids at the time of informed
consent or change in dosage of thyroid
hormones within 6 weeks before informed
consent or any other uncontrolled endocrine
disorder except T2DM. Pre-menopausal women
who were nursing, pregnant, or not practicing
an acceptable method of birth control were also
ineligible.
All patients gave written informed consent
before participation. The trial protocol was
approved by the independent ethics
committees or institutional review boards of
the participating centers. The study was carried
out according to the principles of the
Declaration of Helsinki and the International
Conference on Harmonisation Guideline for
Good Clinical Practice.
Treatments
Following screening, patients underwent a
2-week placebo run-in period. Treatment
assignment was determined using an
interactive voice/web response system and was
stratified by HbA1c at screening [\8.5%
(69 mmol/mol) or C8.5% (69 mmol/mol)].
Eligible patients were randomized (1:1) to
double-blind treatment with either linagliptin
5 mg and LD metformin once daily or HD
metformin twice daily for 14 weeks, followed
by a 1-week follow-up period. Metformin
(immediate release formulation) was initiated
at 500 mg/day and was up-titrated within
2 weeks to a maximum daily dose of 1000 mg
in the LD group and a maximum daily dose of
2000 mg in the HD group. During this 2-week
period, metformin was up-titrated in multiples
of 500 mg every 3–4 days if, in the opinion of
the investigator, no major GI or other events
occurred. If these events occurred, metformin
was down-titrated to the previous tolerated
dose. For the following 12 weeks, the dose of
metformin was unchanged.
Rescue therapy (antihyperglycemic drug
selected by the investigator and taken in
accordance with local prescribing information)
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was initiated if the following criteria were met:
during the first 8 weeks, the patient had a
fasting plasma glucose (FPG) level [240 mg/dL
(13.3 mmol/L) after an overnight fast; from
Weeks 8 to 14, the patient had an FPG level of
[210 mg/dL (11.6 mmol/L) after an overnight
fast. To initiate rescue medication, these criteria
had to be confirmed by two measurements, of
which at least one was to have been performed
after an overnight fast at the investigational
site. If the patient’s hyper- or hypoglycemia
could not be controlled and the investigator
anticipated no further effect from rescue
therapy, the patient was discontinued from
the trial. Glucagon-like peptide-1 analogs,
DPP-4 inhibitors, and metformin were not
allowed as rescue therapy.
Endpoints
The primary efficacy endpoint was the change
from baseline in HbA1c after 14 weeks of
treatment in patients who tolerated a daily
metformin dose of C1000 mg after 2 weeks. The
first key secondary endpoint was a composite
endpoint comprising the proportion of patients
who achieved HbA1c \7.0% (53 mmol/mol) at
Week 14 and without the occurrence of pre-
specified moderate or severe GI events; the
second key secondary endpoint was the
occurrence of pre-specified moderate or severe
GI events during 14 weeks of treatment. The list
of pre-specified GI events included AEs of
abdominal pain, nausea, vomiting, diarrhea,
and decreased appetite. Exact definitions of pre-
specified mild, moderate, and severe GI AEs are
outlined in Table S1 in the electronic
supplementary material (ESM). Other
secondary endpoints included: change from
baseline in FPG after 14 weeks; change from
baseline in HbA1c over time; percentage of
patients who achieved HbA1c B6.5%
(48 mmol/mol) after 14 weeks and without the
occurrence of pre-specified moderate or severe
GI events; percentage of patients who achieved
a C0.5% (6 mmol/mol) reduction in HbA1c
after 14 weeks; composite endpoint comprising
the percentage of patients who achieved a
C0.5% (6 mmol/mol) reduction in HbA1c after
14 weeks without the occurrence of pre-
specified moderate or severe GI events;
percentage of patients who achieved a C0.8%
(9 mmol/mol) reduction in HbA1c after
14 weeks; composite endpoint comprising the
percentage of patients who achieved a C0.8%
(9 mmol/mol) reduction in HbA1c after
14 weeks without the occurrence of pre-
specified moderate or severe GI events;
intensity (mild, moderate, or severe) of pre-
specified GI events during 14 weeks of
treatment as assessed by investigators;
intensity scores (based on visual analog scale)
of pre-specified GI events during 14 weeks of
treatment as assessed by patients; and change
from baseline in body weight over time. Other
efficacy endpoints included the percentage of
patients who achieved HbA1c \7.0%
(53 mmol/mol) and HbA1c B6.5%
(48 mmol/mol) after 14 weeks, and the use of
rescue therapy. Safety assessments included the
frequency and intensity of AEs, including
hypoglycemia and AEs of special interest, and
changes from baseline in vital signs,
electrocardiogram, and clinical laboratory
values.
Statistical Analysis
The primary endpoint was evaluated using an
analysis of covariance (ANCOVA), with
‘treatment’ as a fixed classification effect and
‘baseline HbA1c’ as a linear covariate. This pre-
specified primary analysis was performed on the
full analysis set (FAS1000mg), which comprised
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all randomized and treated patients with a
baseline HbA1c measurement and C1 on-
treatment HbA1c measurement, who tolerated
a daily metformin dose of C1000 mg at the end
of the titration phase. A last observation carried
forward (LOCF) approach was used to replace
missing data. Non-inferiority (with a margin of
0.35%) followed by superiority for the primary
endpoint in a hierarchical sequence was used to
test for the treatment effect of linagliptin ? LD
metformin compared with HD metformin. The
overall significance level was 5%. Sensitivity
analyses were performed to assess the impact of
missing data, important protocol violations,
and premature discontinuation of trial
medication on the primary endpoint.
Sensitivity analyses utilized the FAS (LOCF),
FAS1000mg-completers (LOCF), and per-protocol
set (PPS)1000mg (LOCF) using the same model as
for the primary analysis. Pre-specified subgroup
analyses for the primary endpoint based on
FAS1000mg were performed on several baseline
variables including race, ethnicity, geographical
region, baseline HbA1c, age, gender, time since
diagnosis of diabetes, baseline BMI, and renal
function. For the first key secondary endpoint,
the non-completers considered failure (NCF)
approach was used (e.g., patients who did not
complete 14 weeks were counted as having not
achieved an HbA1c of\7% and no pre-specified
GI AE). For the second key secondary endpoint,
original results were used [original data as
collected, with no imputation or exclusions
(e.g., due to rescue therapy or repeat values)]. A
logistic regression model with treatment and
continuous baseline HbA1c was fitted on the
binary response variable to calculate the
estimate of the odds ratio (OR) of the two
treatment groups. The remaining secondary
endpoints were exploratory. Safety data were
analyzed using descriptive statistics and were
based on the treated set (TS), defined as all
patients treated with C1 dose of randomized
study medication. AEs were coded using the
Medical Dictionary for Drug Affairs (MedDRA)
version 15.0 and are presented by system organ
class and preferred term. AEs of special interest
were analyzed using standardized MedDRA
queries (SMQs; narrow versions) and included
hypersensitivity reactions, skin lesions, hepatic
AEs, renal AEs, and pancreatitis.
RESULTS
Patient Disposition, Demographics,
and Baseline Clinical Characteristics
The first patient was enrolled on November 24,
2011 and the last patient visit occurred on
March 5, 2013. Patients (n = 689) were
randomized to linagliptin ? LD metformin
(n = 344) or HD metformin (n = 345); all
patients received C1 dose of study drug (TS;
Fig. 1). Overall, 661 (95.9%) patients completed
the trial and 28 (4.1%) patients (n = 14 per
group) prematurely discontinued. The most
common reasons for discontinuation were ‘lost
to follow-up’ (1.2%) and ‘refusal to continue
trial medication’ (1.2%) in the linagliptin ? LD
metformin group, and ‘other’ reasons (1.2%) in
the HD metformin group. Of the patients in the
FAS, 42 patients (12.4%) in the linagliptin ? LD
metformin group were excluded from the
FAS1000mg as they did not tolerate a daily
metformin dose of 1000 mg after 2 weeks; by
contrast, no patients were excluded in the HD
metformin group. The imbalance in the
exclusion of patients from the FAS1000mg was
due to the design of this study, which specified
different rules of discontinuation for the two
groups. During the titration phase, patients
who were unable to tolerate the starting dose
of metformin (500 mg/day; both treatment
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groups) or tolerate metformin 1000 mg/day (HD
metformin group only) were withdrawn from
the trial. The FAS1000mg consisted of 639
patients: linagliptin ? LD metformin, n = 298;
HD metformin, n = 341.
Demographic and clinical characteristics
were similar between treatment groups
(Table 1). The overall mean (SD) age, BMI, and
HbA1c at baseline were 53.0 (10.7) years,
29.0 (5.6) kg/m2, and 8.0 (0.9) % [64
(10) mmol/mol], respectively. Just under half
of patients had diabetes for B1 year (47.3%).
The study population consisted primarily of
Asian (47.6%), American Indian/Alaska Native
(26.7%), and White patients (25.3%).
Based on the TS, the mean (SD) metformin
dose at Week 2 in the linagliptin ? LD
metformin group was 940.8 (161.7) mg/day
(median 1000 mg/day), with 88.2% of patients
receiving 1000 mg/day and 11.8% receiving
500 mg/day. The mean (SD) metformin dose at
Week 2 in the HD metformin group was
1798.5 (347.6) mg/day (median 2000 mg/day),
with 71.8% of patients receiving 2000 mg/day,
16.2% receiving 1500 mg/day, and 12.1%
receiving 1000 mg/day.
Efficacy Outcomes
Change in HbA1c and FPG
Both groups showed clinically meaningful
reductions in HbA1c levels at Week 14. The
adjusted mean (SE) change in HbA1c from
baseline was -0.99 (0.05) % [-11 (1)
mmol/mol] for linagliptin ? LD metformin
and -0.98 (0.04) % [-11 (0) mmol/mol] for
HD metformin, resulting in a treatment
difference of -0.01 (0.06) % [95% confidence
interval (CI) -0.13, 0.12] [0 (1) mmol/mol (95%
CI -1, 1)] (P = 0.8924). Treatment with
linagliptin ? LD metformin was non-inferior
(P\0.0001), but not superior (P = 0.8924), to
HD metformin. Figure 2a shows the change in
HbA1c over time.
Fig. 1 Patient disposition. aAll patients who were treated
with C1 dose of study medication. bAll patients who had a
baseline and C1 on-treatment HbA1c measurement. cAll
patients who had a baseline and C1 on-treatment HbA1c
measurement, who tolerated a daily metformin dose of
C1000 mg at the end of the titration phase. AE adverse
event, FAS full analysis set, HbA1c glycated hemoglobin,
HD high dose, LD low dose, TS treated set
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The sensitivity analyses were consistent with
the results of the primary analysis: the
comparator-adjusted mean (SE) change in
HbA1c from baseline at Week 14 was
-0.01 (0.06) % (95% CI -0.13, 0.12) [0
(1) mmol/mol (95% CI -1, 1)] in the FAS
Table 1 Baseline demographics and clinical characteristics





Patients (TS), na 344 345
Males, n (%) 169 (49.1) 158 (45.8)
Race, n (%)
American Indian/Alaska native 85 (24.7) 99 (28.7)
Asian 163 (47.4) 165 (47.8)
Black or African American 0 (0.0) 3 (0.9)
White 96 (27.9) 78 (22.6)
Age, years, mean (SD) 53.1 (10.7) 52.9 (10.7)
Body weight, kg, mean (SD) 76.7 (18.8) 76.0 (18.8)
BMI, kg/m2, mean (SD) 29.0 (5.7) 29.0 (5.6)
Renal function (eGFR) according to MDRD, n (%)
Normal (C90 mL/min/1.73 m2) 153 (44.5) 174 (50.4)
Mild impairment (60 to\90 mL/min/1.73 m2) 176 (51.2) 169 (49.0)




HbA1c, %, mean (SD) 8.0 (1.0) 8.0 (0.8)
HbA1c, mmol/mol, mean (SD) 64 (10) 64 (9)
HbA1c\8.5% (69 mmol/mol), n (%) 206 (69.1) 248 (72.7)
FPG, mg/dL, mean (SD) 158.2 (41.0) 155.0 (37.7)
Duration of diabetes, n (%)
B1 year 136 (45.6) 166 (48.7)
[1 to B5 years 103 (34.6) 112 (32.8)
[5 years 59 (19.8) 63 (18.5)
BMI body mass index, eGFR estimated glomerular ﬁltration rate, FPG fasting plasma glucose, HbA1c glycated hemoglobin,
HD high dose, LD low dose, MDRD Modiﬁcation of Diet in Renal Disease, SD standard deviation
a TS—all patients who were treated with C1 dose of study medication
b FAS1000mg—all patients who had a baseline and C1 on-treatment HbA1c measurement, who tolerated a daily metformin
dose of C1000 mg at the end of the titration phase
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(LOCF), -0.01 (0.07) % (95% CI -0.14, 0.12) [0
(1) mmol/mol (95% CI -2, 1)] in the FAS1000mg-
completers (LOCF), and -0.03 (0.06) % (95% CI
-0.15, 0.10) [0 (1) mmol/mol (95% CI -2, 1)] in
the PPS1000mg (LOCF).
The proportion of patients achieving HbA1c
\7.0% (53 mmol/mol) at Week 14 was similar
in both groups (linagliptin ? LD metformin
56.7%; HD metformin 56.3%). Overall, 70.8%
of patients in the linagliptin ? LD metformin
group and 75.4% in the HD metformin group
achieved a C0.5% (6 mmol/mol) reduction in
HbA1c after 14 weeks. The proportion of
patients achieving HbA1c \6.5%
(48 mmol/mol) and a C0.8% (9 mmol/mol)
reduction in HbA1c after 14 weeks was also
similar (Table S2 in the ESM).
For both treatment arms, clinically relevant
reductions in HbA1c were seen for all
subgroups. None of the subgroups showed any
notable differences between treatments, and no
treatment by subgroup interactions was
significant.
The adjusted mean (SE) change from
baseline in FPG at Week 14 was
-24.5 (1.5) mg/dL for linagliptin ? LD
metformin and -26.6 (1.4) mg/dL for HD
metformin [comparator-adjusted mean (SE)
change: ?2.0 (2.1) mg/dL, 95% CI -2.1, 6.1,
P = 0.3352] (Fig. 2b). Rescue medication was
required by one patient in the linagliptin ? LD




The proportion of patients who had pre-
specified GI events of moderate or severe
intensity during the treatment period was
similar in both treatment groups
(linagliptin ? LD metformin 8.4%; HD
Fig. 2 Mean changes in HbA1c and FPG over time.
a Adjusted mean change in HbA1c from baseline over time
from the mixed model repeated measurements analysisa
(FAS1000mg; OC). b Adjusted
b mean change in FPG from
baseline over time up to 14 weeks (FAS1000mg; LOCF).
aModel includes treatment, continuous baseline HbA1c in
addition to week repeated within patient, week by baseline
HbA1c interaction, and week by treatment interaction.
bANCOVA model includes treatment, continuous baseline
HbA1c, and continuous baseline FPG. FAS1000mg—all
patients who had a baseline and C1 on-treatment HbA1c
measurement, who tolerated a daily metformin dose
of C1000 mg at the end of the titration phase. ANCOVA
analysis of covariance, FAS full analysis set, FPG fasting
plasma glucose, HbA1c glycated hemoglobin, HD high dose,
LD low dose, LOCF last observation carried forward, OC
observed cases, SE standard error
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metformin 8.2%; OR 1.022, 95% CI 0.6, 1.8,
P = 0.9397) (Table 2). The most frequently
reported pre-specified GI events of moderate or
severe intensity were diarrhea (linagliptin ? LD
metformin 6.4%; HD metformin 5.6%) and
abdominal pain (linagliptin ? LD metformin
2.3%; HD metformin 3.2%). The number of
patients with pre-specified GI events of any
intensity (mild, moderate, or severe) was lower in
the linagliptin ? LD metformin group compared
with the HD metformin group. This difference was
primarily due to fewer patients having mild GI
events compared with the HD metformin group
(18.5% versus 24.3%, respectively). The most
frequently reported pre-specified GI events of
mild intensity were diarrhea (linagliptin ? LD
metformin 12.1%; HD metformin 15.8%) and
abdominal pain (linagliptin ? LD metformin
3.4%; HD metformin 6.2%).
In both groups, most patients had the first GI
event during the first 2 weeks (Figure S1 in the
ESM). In the FAS1000mg, the adjusted mean (SE)
visual analog scores for pre-specified GI event
severity assessed by patients were similar in
both groups [linagliptin ? LD metformin 4.9
(0.2); HD metformin 4.4 (0.2)].
Change in Composite Endpoint
The proportion of patients who achieved HbA1c
\7.0% (53 mmol/mol) without occurrence of
pre-specified moderate or severe GI events was
the same in both groups (linagliptin ? LD
metformin 51.3%; HD metformin 51.3%; OR
0.960, 95% CI 0.67, 1.37, P = 0.8201). The
proportion of patients who achieved C0.5%
(6 mmol/mol) reduction in HbA1c without
occurrence of pre-specified moderate or severe
GI events after 14 weeks was similar
(linagliptin ? LD metformin 65.1%; HD
metformin 69.2%). Patients who achieved
HbA1c \6.5% (48 mmol/mol) without
occurrence of pre-specified moderate or severe
GI events and who achieved C0.8%
(9 mmol/mol) reduction in HbA1c without
occurrence of pre-specified moderate or severe
GI events after 14 weeks were similar between
the groups (Table S2 in the ESM).
AEs and Hypoglycemia
The overall frequency of any AE and drug-
related AEs was comparable between groups,
and AEs leading to discontinuation of trial
medication were low (Table 3). AEs of special
interest were infrequent and no cases of
pancreatic cancer were observed. One patient
(0.3%) treated with linagliptin ? LD metformin
and seven patients (2.0%) treated with HD
metformin had serious AEs requiring
hospitalization. One patient treated with
linagliptin ? LD metformin had a serious AE
that did not require hospitalization.
The highest frequency of AEs was reported for
the system organ class GI disorders
(linagliptin ? LD metformin 33.7%; HD
metformin 35.1%). GI AEs leading to
discontinuation of trial medication were low
and included only abdominal pain
(linagliptin ? LD metformin 0.6%; HD
metformin 0.3%). Investigator-reported drug-
related GI AEs were reported in 17.7% of
patients treated with linagliptin ? LD
metformin and 19.7% treated with HD
metformin. The most common drug-related GI
AEs ([2% in either group) were diarrhea (9.3%
versus 12.8%), abdominal pain (4.9% versus
5.5%), and nausea (4.4% versus 4.9%),
respectively. Two patients reported serious GI
AEs: acute pancreatitis in the linagliptin ? LD
metformin group, and abdominal pain and
epiploic appendagitis (acute inflammation of an
epiploic appendix) in the HD metformin group.
The incidence of investigator-reported
hypoglycemia was low (linagliptin ? LD
metformin 0.6%; HD metformin 1.7%); no
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Table 2 Pre-speciﬁed GI events associated with metformin as assessed by the investigator






Patients with moderate or severe GI events, n (%) 25 (8.4) 28 (8.2)
OR (95% CI) versus metformin alone 1.022 (0.582, 1.796)
Patients with any GI event, n (%) 73 (24.5) 98 (28.7)
Patients by intensity, n (% of FAS1000mg)
b
Mild 55 (18.5) 83 (24.3)
Moderate 24 (8.1) 27 (7.9)
Severe 4 (1.3) 1 (0.3)
Number of GI events, n 157 219
Events by intensity, n (% of total events)
Mild 114 (72.6) 153 (69.9)
Moderate 37 (23.6) 65 (29.7)
Severe 6 (3.8) 1 (0.5)
Test of association between GI AE severity and treatment
Chi-square P value 0.0314
Fishers exact P value 0.0308
Patients with mild GI events, n (%)
Diarrhea 36 (12.1) 54 (15.8)
Abdominal pain 10 (3.4) 21 (6.2)
Nausea 13 (4.4) 16 (4.7)
Vomiting 5 (1.7) 6 (1.8)
Decreased appetite 3 (1.0) 8 (2.3)
Patients with moderate or severe GI events, n (%)
Diarrhea 19 (6.4) 19 (5.6)
Abdominal pain 7 (2.3) 11 (3.2)
Nausea 4 (1.3) 8 (2.3)
Vomiting 5 (1.7) 1 (0.3)
Decreased appetite 3 (1.0) 3 (0.9)
Pre-speciﬁed GI events included AEs of abdominal pain, nausea, vomiting, diarrhea, and decreased appetite
AE adverse event, CI conﬁdence interval, GI gastrointestinal, HD high dose, LD low dose, OR odds ratio
a Full analysis set (FAS1000mg)—all patients who had a baseline and C1 on-treatment HbA1c measurement, who tolerated a
daily metformin dose of C1000 mg at the end of the titration phase
b Patients could be counted in more than one category
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severe hypoglycemic events requiring assistance
were reported. Slight decreases in body weight
were observed in both groups: the adjusted
mean (SE) change from baseline after 14 weeks
was -0.44 (0.14) kg in the linagliptin ? LD
metformin group and -1.05 (0.13) kg in the
HD metformin group; the treatment difference
was 0.62 (0.19) kg (95% CI 0.25, 0.98,
P = 0.0011). There were no clinically relevant
changes in vital signs or laboratory parameters
in either group, and no patient had any cardiac
or cerebrovascular event confirmed by the
clinical event committee. No patient had any
confirmed case of hospitalization due to heart
failure.
DISCUSSION
Metformin is predominantly recommended as
first-line therapy for the treatment of T2DM [1, 3],
unless it is contraindicated. In clinical practice,
metformin can be up-titrated to a maximum daily
dose of 2550 mg [11], with maximum efficacy
achieved at 2000 mg [5]. Metformin is well
tolerated in the majority of patients; however,
GI events are common and can occur in up to 30%
of patients [5, 12–14]. These complications tend
tooccur soonafter initiationof therapy [1, 15] and
in particular when metformin is used at higher
doses [5, 16]. To minimize GI events and improve
tolerability, guidelines recommend that
metformin is initiated at a low dose and is
gradually up-titrated to the maximum tolerated
dose [1]. Although in many patients GI events
tend to resolve upon continued treatment, or
with a reduction in metformin dose, the
symptoms can be severe enough to limit or
complicate optimal dose titration and therefore
negatively impact treatment adherence and long-
term glycemic control [17].
This trial evaluated whether linagliptin
5 mg ? LD metformin once daily is a potential
Table 3 Overall summary of AEs (TS)




Patients, n 344 345
Any AE, n (%) 219 (63.7) 229 (66.4)
Severe AEs, n (%) 12 (3.5) 9 (2.6)
Investigator-reported, drug-related AEs, n (%) 71 (20.6) 80 (23.2)
AEs leading to discontinuation of trial medication, n (%) 3 (0.9) 3 (0.9)
Serious AEs, n (%) 2 (0.6) 7 (2.0)
Patients with AEs of special interest, n (%)
Hypersensitivity reactions 1 (0.3) 1 (0.3)
Cutaneous skin lesions 0 (0.0) 0 (0.0)
Hepatic AEs 5 (1.5) 9 (2.6)
Renal AEs 0 (0.0) 0 (0.0)
Pancreatitis 1 (0.3) 0 (0.0)
TS—all patients who were treated with C1 dose of study medication
AE adverse event, HD high dose, LD low dose, TS treated set
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alternative treatment to HD metformin twice
daily with a focus on glycemic control and pre-
specified GI events in treatment-naı¨ve patients
with T2DM and insufficient glycemic control.
The results show that linagliptin ? LD metformin
and HD metformin were equally effective and
both substantially reduced HbA1c and FPG levels.
Furthermore, more than half of patients in both
arms achieved a clinically relevant HbA1c target
of\7.0% (53 mmol/mol). Since glycemic efficacy
was similar in the combination group in the
context of a substantially lower dose of
metformin, linagliptin ? LD metformin may be
an appropriate treatment alternative, especially
in patients who cannot tolerate higher doses of
metformin. In contrast to the design of the
present study, the effects of combination
therapy with linagliptin ? metformin have been
investigated previously in the setting of
equivalent doses of metformin monotherapy [8]
and linagliptin monotherapy [18]. In the study
by Haak et al. [8], initial combination of
linagliptin (2.5 mg twice daily) with LD (500 mg
twice daily) or HD (1000 mg twice daily)
metformin achieved superior glucose-lowering
efficacy compared with the equivalent doses of
metformin monotherapy. In the study by Ross
et al. [18], initial combination therapy with
linagliptin (5 mg once daily) and metformin
(up-titrated to 1000 mg twice daily) significantly
improved glycemic control compared with the
equivalent dose of linagliptin monotherapy.
Studies of other DPP-4 inhibitors have also
shown significant clinical benefit when
administered as initial combination therapy
with metformin and compared with the
equivalent dose of metformin monotherapy
[19–23]. Therefore, the combination of
linagliptin and metformin may be an
appropriate choice if glycemic control is not
achieved with metformin monotherapy.
Although controlling hyperglycemia is the
most important property of glucose-lowering
therapies, consideration should be given to
overall tolerability [1]. This is a particular
concern when using combination therapy due
to the potential increase in AEs. When
administering multiple oral antihyperglycemic
drugs, one approach to avoid excessive AEs is to
use a LD combination strategy [7, 24, 25]. This
strategy could be especially useful in patients
who do not tolerate maximum effective doses of
one drug, such as metformin. In this study,
about 30% of patients assigned to HD
metformin could not achieve the maximum
dose of 2000 mg. The proportion of patients
who had pre-specified GI events of moderate or
severe intensity during treatment was similar in
both groups. However, the number of patients
who had pre-specified GI events of any intensity
was lower in the linagliptin ? LD metformin
group, mainly due to fewer patients
experiencing mild GI events. Diarrhea and
abdominal pain were the most commonly
reported GI events, with lower incidences
occurring with linagliptin ? LD metformin.
One possible explanation for the modest
difference in GI events is that forced titration
to maximal dose was not employed. GI events
are more likely to occur soon after initiation of
metformin [1, 15], an observation supported by
this study. Previous studies have shown that
even at equal metformin doses, patients
receiving a DPP-4 inhibitor ? metformin
single-pill combination tend to experience
fewer GI AEs compared with those receiving
metformin alone [19, 26, 27]. The potential
mechanism of this effect is currently unknown.
Despite significant improvements in
glycemic control in both treatment groups,
the incidence of hypoglycemia was low with
no episodes of severe hypoglycemia requiring
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assistance. In addition, small decreases in body
weight were seen in both groups.
This study was based on a relatively short
duration of 14 weeks, which did not allow for
assessments of long-term safety or durability of
treatment efficacy. However, in a previous phase
3 study, the largest decrease in HbA1c occurred
during the first 12 weeks of treatment for both
the linagliptin ? metformin combination group
and the metformin monotherapy group.
Furthermore, in this study the maximum effect
for the change in FPG was achieved in both
groups by Week 2, which suggests that most of
the expected reduction in HbA1c was achieved
by Week 14. The combination of linagliptin plus
metformin has also been shown to provide
durable HbA1c reduction for up to 2 years [10].
This study did not assess whether patients
receiving HD metformin and who were
experiencing GI AEs would benefit from
switching to linagliptin ? LD metformin,
which may have minimized the GI AEs
without compromising the overall glucose-
lowering efficacy. In the present study, patients
received immediate release metformin;
however, extended release formulations of
metformin are available which are associated
with fewer GI AEs compared with immediate
release metformin [12]. Other limitations
include the lack of a forced titration scheme to
up-titrate the dose of metformin and, because
the study was conducted primarily (74%) in
Asian and American Indian/Alaska native
patients, the possible underrepresentation of
white patients could affect the applicability of
these results to the wider T2DM patient
population.
CONCLUSION
This study shows that treatment with
linagliptin ? LD metformin once daily
provided similar glucose control to HD
metformin twice daily in treatment-naı¨ve
patients with T2DM and insufficient glycemic
control. The overall safety profile of
linagliptin ? LD metformin combination
therapy was comparable to HD metformin
monotherapy, with a low incidence of
hypoglycemia in both groups. Protocol-pre-
specified moderate and severe GI events were
similar for the two treatments, although the
linagliptin ? LD metformin group was
associated with fewer mild GI events. Our
findings suggest that linagliptin ? LD
metformin once daily may be an alternative
treatment option in patients who cannot
tolerate metformin doses [1000 mg/day.
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